Stock analysis, trade plans, and proprietary indicators by Trend Edge.
About Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: April 24, 2012
Headquarters: 10880 Wilshire Boulevard, Los Angeles, CA, United States, 90024
Founder-Led: Yes — Alan Auerbach (Founder, Chairman, President, CEO & Secretary)
Key Metrics
Current Price
$7.49
Market Cap
$369M
Float
39.1M
Shares Outstanding
50.9M
P/E (Forward)
3.46
P/E (TTM)
11.90
Price/Sales (TTM)
1.62
vs. Analyst Target
-33.2% to analyst PT
Profit Margin
13.62%
Operating Margin (TTM)
22.67%
Revenue (TTM)
$228M
Earnings Growth (YoY)
-34.40%
Dividend Rate
None
Analyst Target Price
$5.00 (2 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
$225M
-$60.0M
$186M
-$35.7M
2021
$253M
-$29.1M
$189M
-$4.7M
2022
$228M
$2,000
$173M
$21.9M
2023
$236M
$21.6M
$173M
$47.5M
2024
$230M
$30.3M
$166M
$48.1M
2025
$228M
$31.1M
$170M
$53.3M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Mar 2025
$46.0M
$3.0M
Jun 2025
$52.4M
$5.9M
Sep 2025
$54.5M
$8.8M
Dec 2025
$75.5M
$13.4M
Ownership & Float
Insider Ownership
15.4%
Institutional Ownership
73.8%
Short Float
10.6%
% of All Funds Holding
1.77%
Number of Funds Holding
137
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$6.88
Near-term / short-term trend
Weekly
40-Week SMA
$5.86
Medium-term trend
Weekly
80-Week SMA
$4.50
Cyclical trend (business cycle)
Weekly
200-Week SMA
$3.97
Secular trend (multi-year)
Monthly
10-Month SMA
$6.00
Near-term monthly trend
Monthly
20-Month SMA
$4.59
Medium-term monthly trend
Monthly
40-Month SMA
$4.15
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$3.10
support
1.92x
8 months ago
Historical Earnings Reactions (57 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
-1.33%
0.06%
50.88%
32.51%
-37.82%
1 Day
-0.69%
-0.27%
45.61%
39.99%
-48.01%
1 Week
1.83%
1.51%
52.63%
74.16%
-44.74%
2 Weeks
7.23%
1.92%
55.36%
154.65%
-48.53%
1 Month
6.74%
3.08%
51.79%
154.16%
-55.06%
Next earnings: May 14, 2026 (3 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
0.8%
64.3%
14
Feb
5.5%
50.0%
14
Mar
0.2%
50.0%
14
Apr
-3.9%
42.9%
14
May
4.7%
64.3%
14
Jun
-2.5%
50.0%
14
Jul
18.8%
57.1%
14
Aug
5.0%
57.1%
14
Sep
-0.5%
57.1%
14
Oct
-8.6%
35.7%
14
Nov
13.5%
50.0%
14
Dec
2.3%
28.6%
14
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
0.16%
49.4%
662
Tuesday
0.11%
47.4%
724
Wednesday
0.45%
48.8%
722
Thursday
-0.06%
44.6%
709
Friday
0.12%
47.4%
709
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 73.8%
Insider Transactions — Smart Summary
Total insider ownership: 15.4%
Founder-led management: Alan Auerbach (Founder, Chairman, President, CEO & Secretary)
12-Month Insider Activity Summary
Total Filings
14
Net Value
-$549,733.598
Net Shares Change
-258,053
% of Float
-0.7%
C-Suite Filings
6
Clusters Detected
3
Key Insiders
Name
Title
Net Value
Filings
Activity
Cesano Alessandra
-$132,219
2
N/A
MILLER MICHAEL PATRICK
-$97,228
1
1 sell
Senderowicz Adrian
-$91,800
1
N/A
MOYES JAY M
-$74,800
1
N/A
NOUGUES MAXIMO F
Chief Financial Officer
-$64,186.952
1
N/A
HUNT DOUGLAS M
The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer.
-$52,695.275
1
N/A
Dorval Allison
-$39,474
1
N/A
WILSON TROY EDWARD
-$36,720
1
N/A
Transaction Clusters
Period
Filings
Insiders
Net Value
Seniority
2025-06-17 – 2025-06-17
6
6
-$311,563
2025-07-10 – 2025-07-22
4
4
-$318,883.471
3 C-suite
2026-01-08 – 2026-01-08
3
3
-$321,759.127
3 C-suite
Significant Filings
Date
Insider
Title
Net Value
Price After
2025-11-13
MILLER MICHAEL PATRICK
-$97,228
Transaction at $4.86, now +54.1%
2026-01-08
NOUGUES MAXIMO F
Chief Financial Officer
-$64,186.952
Transaction at $5.86, now +27.7%
2026-01-08
HUNT DOUGLAS M
The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer.
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Puma Biotechnology Inc
(PBYI) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.